-
1.发明申请mRNA Ratios in Urinary Sediments and/or Urine as a Prognostic and/or Theranostic Marker for Prostate Cancer 有权尿沉渣和/或尿液中的mRNA比例作为前列腺癌的预后和/或前列腺标志物公开(公告)号：US20100021884A1
公开(公告)日：2010-01-28
申请号：US11794048
申请日：2005-12-23
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57434 , G01N2333/96455
摘要： Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and PSA expression in a urine sample and (b) correlating the value of the PCA3/PSA ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of PSA in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of PSA; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.
摘要翻译： 本文描述了受试者中前列腺癌预后的方法和试剂盒。 方法包括：（a）确定尿液样品中PCA3和PSA表达的比例，以及（b）将PCA3 / PSA比值与患者前列腺癌的侵袭性和死亡风险相关联。 还描述了用于预测前列腺癌的试剂盒。 更具体地，本发明的特征在于一种用于在患者的生物样品中预测前列腺癌的方法，包括：评估前列腺癌特异性PCA3 mRNA的量和生物样品中的PSA量; 确定该量的前列腺癌特异性PCA3 mRNA与PSA量的比值; 将所述比值与至少一个预定临界值进行比较，其中高于所述预定临界值的比率值指示与低于所述预定临界值的比率值相比较，前列腺癌死亡风险更高。
-
2.发明申请SPECIFIC METHOD OF PROSTATE CANCER DETECTION BASED ON PCA3 GENE, AND KITS THEREFOR 审中-公开基于PCA3基因的前列腺癌检测特异性方法及其应用公开(公告)号：US20090233285A1
公开(公告)日：2009-09-17
申请号：US12249519
申请日：2008-10-10
申请人： Jack A. Schalken , Gerald Verhaegh , Daphne Hessels , Frank Smit
发明人： Jack A. Schalken , Gerald Verhaegh , Daphne Hessels , Frank Smit
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： The present invention relates, in general, to prostate cancer. More specifically, the present invention relates to a method to diagnose prostate cancer in a patient by detecting a PCA3 sequence, and more particularly a PCA3 RNA, the PCA3 sequence detected in a sample from the patient being specifically associated with prostate cancer. In a particular embodiment the method and kit enables an amplification of a PCA3 RNA through an exon-exon junction of a spliced PCA3 mRNA. The invention also relates to methods and kits to detect such an amplified PCA3 RNA, using a probe which spans the amplified exon-exon junction. In particular the methods and kits are designed to detect a PCA3 RNA which lacks one intron or more, and in particular case is intron-less. The invention further relates to a method of detecting PCA3 RNA expressed in non-prostate tissue or cells of the urinary tract, that comprises PCA3 intron 3.
摘要翻译： 本发明一般涉及前列腺癌。 更具体地，本发明涉及通过检测PCA3序列，特别是PCA3 RNA，在来自与前列腺癌特异性相关的患者样品中检测到的PCA3序列来诊断患者中的前列腺癌的方法。 在一个具体实施方案中，该方法和试剂盒能够通过拼接的PCA3 mRNA的外显子 - 外显子连接扩增PCA3 RNA。 本发明还涉及使用跨越扩增的外显子 - 外显子连接的探针来检测这种扩增的PCA3 RNA的方法和试剂盒。 特别地，所述方法和试剂盒被设计用于检测缺少一个或多个内含子的PCA3RNA，特别是内含子。 本发明还涉及一种检测在非前列腺组织或尿道细胞中表达的PCA3 RNA的方法，其包含PCA3内含子3。
-
公开(公告)号：US20120309007A1
公开(公告)日：2012-12-06
申请号：US13571124
申请日：2012-08-09
IPC分类号： G01N21/64 , G01N33/574 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57434 , G01N2333/96455
摘要： Described herein are method, compositions and kits for prognosis of prostate cancer. The methods comprise: determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The present invention features a method for prognosing prostate cancer in a sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.
摘要翻译： 本文描述了前列腺癌预后的方法，组合物和试剂盒。 方法包括：确定PCA3和尿液样品中前列腺特异性标记物表达的比例，并将PCA3 /前列腺特异性标志物比值与患者前列腺癌的侵袭性和死亡风险相关联。 本发明的特征在于在患者样品中预测前列腺癌的方法，包括：评估前列腺癌特异性PCA3 mRNA的量和样品中前列腺特异性标志物的量; 确定该量前列腺癌特异性PCA3 mRNA的比值超过前列腺特异性标记量; 将所述比值与至少一个预定临界值进行比较，其中高于所述预定临界值的比率值指示与低于所述预定临界值的比率值相比较，前列腺癌死亡风险更高。
-
4.发明申请SPECIFIC METHOD OF PROSTATE CANCER DETECTION BASED ON PCA3 GENE, AND KITS THEREFOR 审中-公开基于PCA3基因的前列腺癌检测特异性方法及其应用公开(公告)号：US20120309006A1
公开(公告)日：2012-12-06
申请号：US13565592
申请日：2012-08-02
申请人： Jack A. Schalken , Gerald Verhaegh , Daphne Hessels , Frank Smit
发明人： Jack A. Schalken , Gerald Verhaegh , Daphne Hessels , Frank Smit
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： The invention relates to a method to diagnose prostate cancer by detecting a PCA3 sequence. In one embodiment the method and kit enables amplification of PCA3 RNA through an exon-exon junction of a spliced PCA3 mRNA, and methods and kits to detect an amplified PCA3 RNA, using a probe which spans the amplified exon-exon junction. The methods and kits can detect a PCA3 RNA lacking one intron or more. Also provided are methods of detecting PCA3 RNA expressed in non-prostate tissue or cells of the urinary tract, which comprises PCA3 intron 3. In addition, methods are provided to determine whether a sample from a subject contains or lacks prostate cells, by performing a hybridization and/or amplification reaction on RNA from the sample to detect the presence or level of PCA3 RNA that lacks at least one intron and distinguishing a prostate cell from a non-prostate cell.
摘要翻译： 本发明涉及通过检测PCA3序列诊断前列腺癌的方法。 在一个实施方案中，该方法和试剂盒可以通过拼接的PCA3 mRNA的外显子 - 外显子连接扩增PCA3 RNA，以及使用跨越扩增的外显子 - 外显子连接的探针来检测扩增的PCA3 RNA的方法和试剂盒。 方法和试剂盒可检测缺少一个内含子或更多的PCA3 RNA。 还提供了检测在非前列腺组织或尿道细胞中表达的PCA3 RNA的方法，其包含PCA3内含子3.此外，提供了用于确定来自受试者的样品是否含有或缺乏前列腺细胞的方法，通过进行 检测来自样品的RNA的杂交和/或扩增反应，以检测缺少至少一个内含子并区分前列腺细胞与非前列腺细胞的PCA3RNA的存在或水平。
-
公开(公告)号：US20120142553A1
公开(公告)日：2012-06-07
申请号：US13379823
申请日：2010-06-22
CPC分类号： C12Q1/6886 , C12Q2600/112
摘要： The present invention relates to methods for establishing the presence, or absence, of a kidney, or renal, tumour in a human individual suspected of suffering from kidney, or renal, cancer. Specifically, the present invention relates to methods for establishing the presence, or absence, of a kidney tumour in a human individual suspected of suffering from kidney cancer comprising: a) determining the expression of one or more genes chosen from the group consisting of NDUFA4l2, ANGPTL4, EGLN3, PTHLH, and ATP6V1B1 in a sample originating from said human individual; b) establishing up, or down, regulation of expression of said one or more genes as compared to expression of said respective one or more genes in a sample originating from said human individual not comprising kidney tumour cells or tissue, or from an individual, or group of individuals, not suffering from kidney cancer; and c) establishing the presence, or absence, of a kidney tumour based on the established up- or down regulation of said one or more genes.
摘要翻译： 本发明涉及用于建立在怀疑患有肾或肾癌的人中存在或不存在肾或肾脏肿瘤的方法。 具体地，本发明涉及用于建立在怀疑患有肾癌的人中存在或不存在肾肿瘤的方法，其包括：a）确定选自NDUFA412， ANGPTL4，EGLN3，PTHLH和ATP6V1B1; b）建立或减少所述一种或多种基因的表达的调节，与源自所述人类个体的样品中所述相应的一个或多个基因的表达相比不包括肾肿瘤细胞或组织，或来自个体，或 一组个体，不患肾癌; 以及c）基于建立的所述一个或多个基因的上调或下调来确定肾肿瘤的存在或不存在。
-
6.发明授权公开(公告)号：US07138235B2
公开(公告)日：2006-11-21
申请号：US11085060
申请日：2005-03-22
IPC分类号： C12Q1/68
CPC分类号： C12Q1/68 , C07K14/47 , C12Q1/6886 , C12Q2600/136 , G01N33/57434
摘要： This invention describes the cloning and characterization of the promoter region for the PCA3dd3 gene. This region regulates the PCA3dd3 gene expression by a unique prostate specific transcriptional mechanism. The present invention relates to the use of this promoter region as a tool for prostate cancer treatment and diagnosis and screening of agents which regulate expression of PCA3. In a particular embodiment, the present invention relates to an isolated promoter sequence which comprises an isolated promoter sequence which comprises a sequence as set forth between nucleotide positions 372 to 460 of SEQ ID NO:1, this sequence enabling a prostate-specific modulation of transcription.
摘要翻译： 本发明描述了PCA3Δdd3基因的启动子区域的克隆和表征。 该区域通过独特的前列腺特异性转录机制调节PCA3Δdd3基因表达。 本发明涉及该启动子区域用作前列腺癌治疗和诊断和筛选调节PCA3表达的试剂的工具。 在一个具体实施方案中，本发明涉及分离的启动子序列，其包含分离的启动子序列，其包含如SEQ ID NO：1的核苷酸位置372至460之间所述的序列，该序列能够进行转录前列腺特异性调节 。
-
公开(公告)号：US20120108453A1
公开(公告)日：2012-05-03
申请号：US13122226
申请日：2009-09-29
IPC分类号： C40B30/04
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158
摘要： The present invention relates to methods for diagnosing prostate cancer and especially diagnosing LG, i.e., individuals with good prognosis; HG, i.e., individuals with poor prognosis of primary tumour; PrCa Met, i.e., individuals with poor prognosis and metastasis; and CRPC, i.e., individuals with poor prognosis suffering from aggressive localized disease. Specifically, the present invention relates to method for establishing the presence, or absence, of prostate cancer in a human individual comprising: a) determining the expression of one or more genes chosen from the group consisting of RRM2, HOXC6, TGM4, RORB, HOXDlO, SFRP2, and SNAI2 in a sample originating from said human individual; b) establishing up, or down, regulation of expression of said one or more genes as compared to expression of said respective one or more genes in a sample originating from said human individual not comprising prostate tumour cells or prostate tumour tissue, or from an individual not suffering from prostate cancer; and c) establishing the presence, or absence, of prostate cancer based on the established up- or down regulation of said one or more genes.
摘要翻译： 本发明涉及诊断前列腺癌并特别诊断LG的方法，即具有良好预后的个体; HG，即原发性肿瘤预后差的个体; PrCa Met，即预后和转移不良的个体; 和CRPC，即患有侵袭性局部疾病的预后差的个体。 具体地，本发明涉及建立人类个体中前列腺癌的存在或不存在的方法，其包括：a）确定选自下组的一种或多种基因的表达：RRM2，HOXC6，TGM4，RORB，HOXD10 ，SFRP2和SNAI2来自所述人个体的样品; b）建立或减少所述一种或多种基因的表达与来自所述不包括前列腺肿瘤细胞或前列腺肿瘤组织或来自个体的所述人个体的样品中所述相应的一个或多个基因的表达相比较 不患前列腺癌; 和c）基于所述一个或多个基因的建立的上调或下调来确定前列腺癌的存在或不存在。
-
8.发明申请mRNA RATIOS IN URINARY SEDIMENTS AND/OR URINE AS A PROGNOSTIC AND/OR THERANOSTIC MARKER FOR PROSTATE CANCER 有权尿酸酶和/或尿液中的mRNA比例作为前列腺癌的预防和/或治疗标记公开(公告)号：US20120003640A1
公开(公告)日：2012-01-05
申请号：US13101440
申请日：2011-05-05
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57434 , G01N2333/96455
摘要： Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and (b) correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.
摘要翻译： 本文描述了受试者中前列腺癌预后的方法和试剂盒。 方法包括：（a）确定尿样中PCA3和前列腺特异性标记物表达的比例，以及（b）将PCA3 /前列腺特异性标志物比值与前列腺癌的侵袭性和死亡风险相关联 主题。 还描述了用于预测前列腺癌的试剂盒。 更具体地，本发明的特征在于在患者的生物样品中预测前列腺癌的方法，包括：评估前列腺癌特异性PCA3 mRNA的量和生物样品中前列腺特异性标志物的量; 确定该量前列腺癌特异性PCA3 mRNA的比值超过前列腺特异性标记量; 将所述比值与至少一个预定临界值进行比较，其中高于所述预定临界值的比率值指示与低于所述预定临界值的比率值相比较，前列腺癌死亡风险更高。
-
9.发明授权公开(公告)号：US06897024B2
公开(公告)日：2005-05-24
申请号：US09996953
申请日：2001-11-30
IPC分类号： C07K14/47 , C12Q1/68 , G01N33/574
CPC分类号： C12Q1/68 , C07K14/47 , C12Q1/6886 , C12Q2600/136 , G01N33/57434
摘要： This invention describes the cloning and characterization of the promoter region for the PCA3dd3 gene. This region regulates the PCA3dd3 gene expression by a unique prostate specific transcriptional mechanism. The present invention relates to the use of this promoter region as a tool for prostate cancer treatment and diagnosis and screening of agents which regulate expression of PCA3. In a particular embodiment, the present invention relates to an isolated promoter sequence which comprises an isolated promoter sequence which comprises a sequence as set forth between nucleotide positions 372 to 460 of SEQ ID NO:1, this sequence enabling a prostate-specific modulation of transcription.
摘要翻译： 本发明描述了PCA3Δdd3基因的启动子区域的克隆和表征。 该区域通过独特的前列腺特异性转录机制调节PCA3Δdd3基因表达。 本发明涉及该启动子区域用作前列腺癌治疗和诊断和筛选调节PCA3表达的试剂的工具。 在一个具体实施方案中，本发明涉及分离的启动子序列，其包含分离的启动子序列，其包含如SEQ ID NO：1的核苷酸位置372至460之间所述的序列，该序列能够进行转录前列腺特异性调节 。
-
10.发明授权mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer 有权尿沉渣和/或尿液中的mRNA比值作为前列腺癌的预后和/或前列腺标志物公开(公告)号：US08257924B2
公开(公告)日：2012-09-04
申请号：US13101440
申请日：2011-05-05
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57434 , G01N2333/96455
摘要： Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and (b) correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.
摘要翻译： 本文描述了受试者中前列腺癌预后的方法和试剂盒。 方法包括：（a）确定尿样中PCA3和前列腺特异性标记物表达的比例，以及（b）将PCA3 /前列腺特异性标志物比值与前列腺癌的侵袭性和死亡风险相关联 主题。 还描述了用于预测前列腺癌的试剂盒。 更具体地，本发明的特征在于在患者的生物样品中预测前列腺癌的方法，包括：评估前列腺癌特异性PCA3 mRNA的量和生物样品中前列腺特异性标志物的量; 确定该量前列腺癌特异性PCA3 mRNA的比值超过前列腺特异性标记量; 将所述比值与至少一个预定临界值进行比较，其中高于所述预定临界值的比率值指示与低于所述预定临界值的比率值相比较，前列腺癌死亡风险更高。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.016 秒)
